Characteristics and Outcomes in Cases of US Male Patients with Metastatic Breast Cancer Receiving Abemaciclib in Routine Clinical Practice - Advances in Therapy
Source : https://link.springer.com/article/10.1007/s12325-023-02471-8
Introduction Breast cancer in males constitutes approximately 1% of all breast cancer cases globally. Despite extensive treatment experience with abemaciclib in women with metastatic breast cancer (MBC), real-world evidence in...
Conclusion: Prevalence of male MBC in this dataset was consistent with expected prevalence in the broader population. Most male patients received an abemaciclib-containing regimen in ≥ 3L, with anti-cancer activity observed despite heavy metastatic burden and prior treatments in a metastatic setting.
-
Albert Dekker2yrmales always have more advanced disease
Economic evaluation for palbociclib plus fulvestrant | TCRM
Since there are no direct evidence from head-to-head clinical trials, in order to determine relative efficacy of treatments, indirect treatment comparison (ITC) methods can be used. Higher overall survival (OS)...
Conclusion: From the Italian perspective, a cost-saving profile associated with the use of PAL+FUL for the management of advanced/metastatic HR+/HER2- breast cancer compared to RIB+FUL and ABM+FUL emerged.
-
Albert Dekker2yrnot sure how that is possible may be they used lower doses
Association between cyclin-dependent kinase 4/6 inhibitors and venous thromboembolism: analysis of F.A.E.R.S. data - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/34581647/
Although it is not able to confirm the casual relationship between VTE and CDK4/6 inhibitors, this study suggested signal of VTE reporting in patients receiving CDK4/6 inhibitors, which is likely...
Conclusions: Although it is not able to confirm the casual relationship between VTE and CDK4/6 inhibitors, this study suggested signal of VTE reporting in patients receiving CDK4/6 inhibitors, which is likely to reflect a potential association. The results may enhance physicians' awareness of the potential side effect of VTE associated...
-
Albert Dekker2yrwe all had patients who had it and typically 1-3 months after start
Immunotherapy for HER-2 positive breast cancer
Source : https://www.frontiersin.org/articles/10.3389/fonc.2023.1097983/full
Immunotherapy is a developing treatment for advanced breast cancer. Immunotherapy has clinical significance for the treatment of triple-negative breast cancers and human epidermal growth factor receptor-2 positive (HER2+) breast cancers....
Conclusions/Relevance: Adoptive T-cell immunotherapies and tumor vaccines are emerging as novel approaches to treating breast cancer, but require further study. This article reviews recent advances in immunotherapy for HER2+ breast cancers.
-
Albert Dekker2yrwill see how it works out; so far best outcomes are still in renal and melanoma
Single oral dose acute and subacute toxicity of a c-MET tyrosine kinase inhibitor and CDK 4/6 inhibitor combination drug therapy
Source : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5794732/
c-MET inhibitor, crizotinib, and CDK 4/6 inhibitor, palbociclib, have been evaluated in combination as cancer treatment in vitro. Because the toxicological data for the combination of these drugs is limited,...
Conclusions/Relevance: The findings from the current in vivo toxicity study in mice, which encompassed two time points at 24 hours and 7 days, may help build upon the base knowledge of what is already known in reference to C and P and provide helpful information for future studies of these drugs. We have shown that the combination of C and P...